Uric Acid Lowering Therapy for Gout

Uric acid lowering therapy (ULT) is the pharmacological strategy used to reduce serum urate concentrations in patients with gout, aiming to dissolve existing monosodium urate (MSU) crystals and prevent new deposits from forming. This page covers the mechanism by which ULT agents work, the clinical scenarios that trigger its use, and the decision boundaries that distinguish appropriate from premature or unnecessary prescribing. Understanding ULT is central to long-term gout management, distinct from the acute flare treatments that address symptoms but do not alter the underlying urate burden.

Definition and Scope

Uric acid lowering therapy encompasses any pharmacological intervention that sustainably reduces serum urate below a defined therapeutic target. The American College of Rheumatology (ACR), in its 2020 Guideline for the Management of Gout, conditionally recommends initiating ULT in patients with 2 or more gout flares per year, tophi, or radiographic joint damage attributable to gout. The same guideline sets the primary serum urate target at below 6 mg/dL, with a lower target of below 5 mg/dL for patients with tophi, to accelerate crystal dissolution.

ULT is not synonymous with acute gout treatment. NSAIDs, colchicine, and corticosteroids address the inflammatory response during a flare but do not lower the urate pool. Uric acid testing for gout establishes the baseline serum urate level that determines both the need for ULT and the adequacy of dosing over time.

The three primary pharmacological classes used in ULT are:

  1. Xanthine oxidase inhibitors (XOIs) — reduce uric acid production by blocking the enzyme xanthine oxidase
  2. Uricosurics — increase renal urate excretion by inhibiting tubular reabsorption transporters (primarily URAT1)
  3. Uricases — enzymatically convert urate to the more soluble compound allantoin; reserved for refractory cases

The U.S. Food and Drug Administration (FDA) has approved allopurinol and febuxostat as XOIs, probenecid as a uricosuric, and pegloticase as a recombinant uricase for chronic gout refractory to conventional therapy (FDA drug database).

How It Works

Gout arises when serum urate exceeds the physiological saturation point of approximately 6.8 mg/dL, at which MSU crystals precipitate into synovial fluid and periarticular tissues. ULT works by driving serum urate below this saturation threshold, progressively mobilizing and dissolving the crystal deposits that trigger inflammatory attacks.

Xanthine oxidase inhibitors block the final two steps of purine catabolism. Allopurinol, a purine analogue, is converted to oxypurinol, which competitively inhibits xanthine oxidase. Febuxostat is a non-purine selective inhibitor of xanthine oxidase. Both reduce urate synthesis. The ACR guideline recommends allopurinol as the preferred first-line XOI regardless of renal function, with dose titration starting at no more than 100 mg/day (50 mg/day in patients with chronic kidney disease stage 4 or worse).

Uricosurics such as probenecid block URAT1 and OAT4 transporters in the proximal renal tubule, preventing urate reabsorption and increasing urinary urate excretion. Because uricosurics increase urinary urate load, they are contraindicated in patients with a history of nephrolithiasis or urate overproduction, and require adequate hydration to reduce stone risk.

Pegloticase, the recombinant pegylated uricase, converts urate to allantoin at a rate far exceeding endogenous clearance, capable of reducing serum urate to below 1 mg/dL in responders. Anti-drug antibodies develop in a clinically significant proportion of patients treated with pegloticase as monotherapy, reducing efficacy and increasing infusion reaction risk; the FDA label for pegloticase includes a boxed warning regarding infusion reactions and anaphylaxis (FDA prescribing information for Krystexxa).

An important pharmacodynamic feature of ULT initiation is that crystal mobilization during the early months of therapy can paradoxically trigger gout flares. The ACR guideline therefore recommends concurrent anti-inflammatory prophylaxis — typically low-dose colchicine or low-dose NSAIDs — for at least 3 to 6 months after ULT initiation.

Common Scenarios

ULT is initiated and monitored across a range of clinical presentations. The most common scenarios include:

The broader regulatory context for rheumatology shapes how prescribing guidelines translate into practice standards, including payer coverage criteria tied to documented flare frequency or tophus presence.

Decision Boundaries

Prescribing ULT involves specific thresholds that distinguish appropriate initiation from premature or inappropriate use.

When to start:
1. Confirmed diagnosis of gout (not hyperuricemia alone) by either MSU crystal identification or ACR/EULAR classification criteria scoring ≥8 points
2. Presence of at least one ACR-recognized strong indication: 2+ flares/year, tophi, or gout-related radiographic damage
3. Baseline serum urate established before initiation to allow monitoring of target attainment

When to withhold or defer:
1. Acute flare in progress — ULT is not initiated during an active flare because rapid serum urate shifts can prolong or intensify the inflammatory episode
2. First gout attack without complicating features — the ACR guideline gives a conditional recommendation against ULT after a single uncomplicated flare in a patient without CKD stage ≥3, urate ≥9 mg/dL, or urolithiasis
3. Known HLA-B*58:01 carrier status without appropriate pre-screening — this allele is associated with severe cutaneous adverse reactions (SCAR) to allopurinol, including Stevens-Johnson syndrome and toxic epidermal necrolysis; the FDA label for allopurinol carries relevant safety language, and the ACR guideline conditionally recommends screening in patients of Southeast Asian or African descent before initiation

Monitoring framework:
- Serum urate checked every 2 to 5 weeks during dose titration
- Target confirmed on at least 2 measurements at the therapeutic serum urate level before extending monitoring intervals
- Renal function and complete metabolic panel reviewed at baseline and periodically during allopurinol therapy, given oxypurinol accumulation in CKD
- Febuxostat carries an FDA boxed warning for cardiovascular death risk based on the CARES trial (New England Journal of Medicine, 2018), which found cardiovascular mortality of 4.3% with febuxostat versus 3.2% with allopurinol; this finding informs a label restriction limiting febuxostat to patients who have failed or are intolerant to allopurinol

The distinction between XOIs also carries clinical weight when renal clearance is impaired. Febuxostat is hepatically metabolized and does not require dose adjustment in mild-to-moderate CKD, making it an alternative in patients unable to tolerate allopurinol titration — subject to the cardiovascular risk caveat above.

Gout prevention strategies, including dietary purine reduction, alcohol limitation, and avoidance of fructose-containing beverages, complement but do not replace pharmacological ULT in patients who meet prescribing thresholds. Non-pharmacological measures alone rarely achieve sustained serum urate below 6 mg/dL in patients with established gout. A foundational overview of rheumatologic care is available at the site index.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)